AR110301A1 - Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip - Google Patents
Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gipInfo
- Publication number
- AR110301A1 AR110301A1 ARP170103363A ARP170103363A AR110301A1 AR 110301 A1 AR110301 A1 AR 110301A1 AR P170103363 A ARP170103363 A AR P170103363A AR P170103363 A ARP170103363 A AR P170103363A AR 110301 A1 AR110301 A1 AR 110301A1
- Authority
- AR
- Argentina
- Prior art keywords
- lys
- pro
- glu
- amino acid
- acid residue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1): H₂N-His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Leu-X¹⁴-Glu-X¹⁶-Gln-Arg-Gln-Aib-Glu-Phe-Ile-Glu-Trp-Leu-Lys-Ala-X²⁹-Gly-X³¹-Pro-ser-Aib-Lys-Pro-Pro-Pro-Lys-R¹ (1) en donde X¹⁴ representa un residuo de aminoácido con un grupo de cadena lateral -NH₂ funcionalizado, seleccionado del grupo que consiste en Lys, Orn, Dab, o Dap, en donde el grupo de cadena lateral -NH₂ se funcionaliza por medio de -Z-C(O)-R⁵, en donde Z representa un conector en todas las formas estereoisoméricas y R⁵ es un radical que comprende hasta 50 átomos de carbono y heteroátomos seleccionados entre N y O; X¹⁶ representa un residuo de aminoácido seleccionado entre Glu y Lys; X²⁹ representa un residuo de aminoácido seleccionado entre D-Ala y Gly; X³¹ representa un residuo de aminoácido seleccionado entre His y Pro; R¹ es NH₂ u OH; o una sal o solvato del mismo. Reivindicación 33: Una composición farmacéutica que comprende al menos un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 17 o una sal o solvato de cualquiera fisiológicamente aceptable de cualquiera de ellos, para su uso como fármaco. Reivindicación 35: Un método para el tratamiento de la hiperglucemia, la diabetes tipo 2 o la obesidad en un paciente, comprendiendo el método administrar al paciente una cantidad eficaz de al menos un compuesto de fórmula (1) como se reivindica en una cualquiera de las reivindicaciones 1 a 17 y una cantidad eficaz de al menos otro compuesto útil para el tratamiento de la diabetes, la obesidad, la dislipidemia o la presión arterial elevada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306605 | 2016-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110301A1 true AR110301A1 (es) | 2019-03-13 |
Family
ID=57542936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103363A AR110301A1 (es) | 2016-12-02 | 2017-11-30 | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10519211B2 (es) |
| EP (1) | EP3548062B1 (es) |
| JP (1) | JP6987139B2 (es) |
| KR (1) | KR20190086022A (es) |
| CN (1) | CN109996557B (es) |
| AR (1) | AR110301A1 (es) |
| AU (1) | AU2017369691A1 (es) |
| BR (1) | BR112019011144A2 (es) |
| CA (1) | CA3045474A1 (es) |
| IL (1) | IL266985A (es) |
| MX (1) | MX2019006427A (es) |
| RU (1) | RU2019120203A (es) |
| TW (1) | TW201833131A (es) |
| WO (1) | WO2018100135A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| MX2020010505A (es) | 2018-04-05 | 2021-01-15 | Sun Pharmaceutical Ind Ltd | Analogos novedosos de glp-1. |
| UY38249A (es) | 2018-05-30 | 2019-12-31 | Sanofi Sa | Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico |
| WO2020130749A1 (ko) * | 2018-12-21 | 2020-06-25 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물 |
| TWI764209B (zh) * | 2019-08-01 | 2022-05-11 | 美商美國禮來大藥廠 | Gipr促效劑化合物 |
| BR112022001081A2 (pt) | 2019-08-19 | 2022-05-24 | Lilly Co Eli | Métodos para produzir análogos de incretina |
| KR20210040818A (ko) * | 2019-10-04 | 2021-04-14 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
| WO2021094259A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | Npy2 receptor agonists |
| KR20230045088A (ko) | 2020-08-07 | 2023-04-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 가용성 npy2 수용체 작용제 |
| KR102691149B1 (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CN115975057B (zh) * | 2023-03-16 | 2023-05-16 | 杭州信海医药科技有限公司 | 一种可妥度肽的固相合成方法 |
| CN119241684B (zh) * | 2024-11-22 | 2025-02-25 | 徐州医科大学 | 一种肠促胰岛素类似物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05003335A (es) | 2002-10-02 | 2005-07-05 | Zealand Pharma As | Compuestos de exendina-4 estabilizados. |
| US20080019911A1 (en) | 2005-04-20 | 2008-01-24 | Aimin Xu | Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4 |
| DK1891105T3 (da) | 2005-06-13 | 2012-07-16 | Imp Innovations Ltd | Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd |
| PE20100056A1 (es) | 2008-06-17 | 2010-01-26 | Univ Indiana Res & Tech Corp | Analogos de glucagon como agonistas gip |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| MX2013006304A (es) | 2010-12-22 | 2013-07-02 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad del receptor gip. |
| AR091477A1 (es) | 2012-06-21 | 2015-02-04 | Univ Indiana Res & Tech Corp | Analogos de glucagon que presentan actividad de receptor de gip |
| CN104583233B (zh) | 2012-06-21 | 2018-10-23 | 印第安纳大学研究及科技有限公司 | 表现出gip受体活性的胰高血糖素的类似物 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CA2894765A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| US10131702B2 (en) | 2013-11-06 | 2018-11-20 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| WO2015086732A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
-
2017
- 2017-11-30 AR ARP170103363A patent/AR110301A1/es unknown
- 2017-11-30 TW TW106141761A patent/TW201833131A/zh unknown
- 2017-12-01 RU RU2019120203A patent/RU2019120203A/ru not_active Application Discontinuation
- 2017-12-01 KR KR1020197018793A patent/KR20190086022A/ko unknown
- 2017-12-01 BR BR112019011144A patent/BR112019011144A2/pt not_active Application Discontinuation
- 2017-12-01 EP EP17821489.6A patent/EP3548062B1/en active Active
- 2017-12-01 CN CN201780073307.6A patent/CN109996557B/zh active Active
- 2017-12-01 US US15/829,698 patent/US10519211B2/en active Active
- 2017-12-01 CA CA3045474A patent/CA3045474A1/en not_active Abandoned
- 2017-12-01 AU AU2017369691A patent/AU2017369691A1/en not_active Abandoned
- 2017-12-01 JP JP2019529534A patent/JP6987139B2/ja active Active
- 2017-12-01 MX MX2019006427A patent/MX2019006427A/es unknown
- 2017-12-01 WO PCT/EP2017/081126 patent/WO2018100135A1/en unknown
-
2019
- 2019-05-29 IL IL266985A patent/IL266985A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180155407A1 (en) | 2018-06-07 |
| IL266985A (en) | 2019-07-31 |
| CA3045474A1 (en) | 2018-06-07 |
| JP6987139B2 (ja) | 2021-12-22 |
| JP2019536795A (ja) | 2019-12-19 |
| CN109996557B (zh) | 2024-05-03 |
| KR20190086022A (ko) | 2019-07-19 |
| TW201833131A (zh) | 2018-09-16 |
| RU2019120203A (ru) | 2021-01-14 |
| US10519211B2 (en) | 2019-12-31 |
| AU2017369691A1 (en) | 2019-07-18 |
| CN109996557A (zh) | 2019-07-09 |
| EP3548062A1 (en) | 2019-10-09 |
| BR112019011144A2 (pt) | 2019-10-01 |
| EP3548062B1 (en) | 2022-01-12 |
| MX2019006427A (es) | 2019-08-21 |
| WO2018100135A1 (en) | 2018-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110301A1 (es) | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip | |
| AR110300A1 (es) | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip | |
| AR099975A1 (es) | Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón | |
| CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
| AR094178A1 (es) | Derivados de exendina-4 funcionalizada | |
| PE20241305A1 (es) | Analogos de amilina | |
| UY39786A (es) | Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades | |
| CL2021001332A1 (es) | Agonistas de glp-1r y usos de los mismos. | |
| CL2008003153A1 (es) | Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras. | |
| BR112017008160A8 (pt) | Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| AR110299A1 (es) | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico | |
| AR112480A1 (es) | Composiciones de glp-1 y sus usos | |
| AR105319A1 (es) | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| EA200800564A1 (ru) | Производные ксантина как селективные агонисты нм74а | |
| AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
| CL2009001340A1 (es) | Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto. | |
| CR11200A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k | |
| CU20110208A7 (es) | Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
| AR095114A1 (es) | Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina | |
| AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |